Thermo Fisher Scientific opens new site for manufacturing COVID-19 sample collection products

▴ thermo-fisher-scientific-continue-expanding-meet-sustained-demand-covid19-testing
New facility in Lenexa, Kansas built in six weeks to rapidly expand production of viral transport media

Thermo Fisher Scientific Inc., the world leader in serving science, officially cut the ribbon on its new $40 million facility in Lenexa, Kansas dedicated to viral transport media (VTM) production. The company is also announcing that the site will continue to expand to meet expected sustained demand for COVID-19 testing. The facility has created more than 300 new full-time jobs and added 120,000 square feet of manufacturing capacity.

In early May, Thermo Fisher received a contract from the U.S. government to provide a significant quantity of highly specialized VTM for COVID-19 sample collection. VTM is dispensed into plastic tubes that are used to safely collect and transport clinical specimens containing viruses. This ensures that the sample collected from a COVID-19 nose swab maintains viability while it is shipped to a lab for testing. Thermo Fisher has responded quickly to meet increased demand for VTM by ramping up production in Lenexa from 50,000 units per week to now more than 8 million per week since the new facility began production in early July.

"Thermo Fisher is proud to support virtually every aspect of the global COVID-19 response and our colleagues in Lenexa have played a key role in those efforts," said Gianluca Pettiti, senior vice president and president of the company's Specialty Diagnostics business. "Thanks to their hard work, Lenexa significantly increased production of VTM units. The team has worked with unrelenting intensity to build out and open a new site in just about six weeks. They understood the urgent national need, accepted the challenge and have delivered for the American people."

Company executives and government leaders, including Governor Laura Kelly, U.S. Senator Jerry Moran and Lenexa City Mayor Michael Boehm, will attend the ribbon cutting and ground-breaking ceremony on August 28. The site will allow for social distancing for the 200 guests expected in attendance.

"Widespread testing is a necessary component to keep the American economy running safely," said U.S. Senator Jerry Moran. "Thermo Fisher has stepped up to produce additional test tubes to help meet the national demand for COVID-19 testing and has created 300 new jobs by expanding its manufacturing base in Lenexa. Kansans never fail to do their part in our country's time of need, and this is no different. Thermo Fisher's ability to manufacture test tubes and significantly increase production is important for making certain Americans can feel secure in their health and safely return to work."

"I'm grateful to the team at Thermo Fisher for the many ways they've stepped up for the health and safety of people in Kansas and across the country," Governor Laura Kelly said. "This facility will do important work innovating and supporting the tools we have to fight this pandemic. I applaud Thermo Fisher's commitment to this critical endeavor."

To ensure accuracy of COVID-19 test results, VTM must be manufactured and dispensed into tubes in an aseptic environment. The new facility is dedicated to accelerating production and ensuring quality control by utilizing the proven blueprint for high-quality VTM production that has been developed in Lenexa. In addition to supporting America's pandemic response, the products will be used for collection and sampling for flu and other viruses.

Tags : #ThermoFisherScientificInc #ViralTransportMedia #USGovt #GianlucaPettiti #LauraKelly #JerryMoran

About the Author


Team Medicircle

Related Stories

18 Jun

FDA approves nasal antihistamine for nonprescription use

Seasonal allergies affect millions causing nasal congestion, runny nose and sneezing. Approval of Asteopro (Azelastine Hydrochloride nasal spray 0.15%) can help many patients with allergies.

View
23 Dec

Glenmark collaborates with Menarini for commercializing Ryaltris nasal spray across Europe

The licensing agreement will be effective in 33 countries throughout the European region including France, Italy, and Spain

View
18 Dec

Research on preventative nasal spray, which protects against COVID-19 and common cold, published in leading peer-reviewed academic journals

Research on a novel nasal spray therapy, INNA-051, which has been shown to reduce COVID-19 viral replication by up to 96 percent in a gold standard ferret study, has been published in two leading international peer-reviewed journals.

View
07 Oct

Glenmark Pharmaceuticals receives ANDA approval for Dimethyl Fumarate Delayed-Release Capsules

Glenmark Pharmaceuticals Inc., USA has been granted final approval by the U.S. FDA for Dimethyl Fumarate DR Capsules, the generic version of Tecfidera

View
18 Aug

Glenmark appoints Dipankar Bhattacharjee to its Board of Directors

Glenmark Pharmaceuticals announced the appointment of Mr Dipankar Bhattacharjee as Independent Non-Executive Director on the Board of the organization

View
30 Jul

Food Allergies: All that you have to know

Skin prick testing can in some cases produce bogus negative or bogus positive outcomes.

View
21 May

Cipla receives final approval for Migranal

Cipla receives final approval for generic version of Migranal (Dihydroergotamine Mesylate Nasal Spray) with a Competitive Generic Therapy Designation

View
12 May

Hikma Announces the Launch of Propofol Injectable Emulsion, USP

Hikma responds to COVID-19 shortage with launch of Propofol Injectable Emulsion, USP. Sedative for patients on ventilators currently in short supply in the US

View
28 Feb

Glenmark Pharma Signs an Exclusive Licensing Agreement with Hikma Pharmaceuticals

Under the terms of the agreement, Glenmark will be responsible for the continued development and regulatory approval of Ryaltrisâ„¢ by the US FDA, while Hikma will be responsible for the commercialization of Ryaltrisâ„¢ in the US.

View

-Advertisements-




Trending Now

The Digital Sleep Thief: How Night-time Screen Addiction is Robbing You of Bed-time RestApril 02, 2025
KKR Launches ‘Knight Bite’ – A Digital Series That Serves Up Food, Fun, and Cricket!April 02, 2025
Crompton rolls out its all new range of Aura, Avancer & Jedi Air Coolers for an effortless summer cooling experienceApril 02, 2025
CARE Hospitals, Hi-Tech City Strengthens Orthopaedics Department with Renowned SurgeonsApril 02, 2025
World Autism Awareness Day: Breaking the Chains of Stigma in IndiaApril 02, 2025
From Scroll to Squint: How Reels Are Reshaping Your VisionApril 02, 2025
Moscow Center for Diagnostics and Telemedicine Receives License for Radiology Residency ProgramApril 02, 2025
CARE Hospitals Launches AI-Powered Non-Invasive Therapy – An innovative modality introduced in Telangana & Andhra PradeshApril 02, 2025
High-Rise Heart Attacks: Are Skyscrapers Turning Survival into a Race Against Time?April 02, 2025
DCDC’s $150 Crore Expansion: Can Innovative Clinics End India's Kidney Crisis?April 02, 2025
Medanta Rolls Out ‘Colon Tunnel on Wheels’ to Drive Awareness on Colorectal Cancer Prevention & Early DetectionApril 01, 2025
Zigly launches 2 pet hospitals, opens 4 new stores; expects ARR to more than double in 1-2 yearsApril 01, 2025
University of Leeds Announces International Masters Regional Scholarships for 2025April 01, 2025
Avantor Recognized with Two Prestigious Awards at Asia-Pacific Biopharma Excellence Awards 2025April 01, 2025
Foundation Stone Laid for Madhav Netralaya Eye Hospital & Research CentreApril 01, 2025
Doomscrolling at Midnight: How Indians Are Sacrificing Sleep for ScreensMarch 31, 2025
Essential Medicines Price Surge: Are Patients Paying the Price?March 31, 2025
Prioritize your health during the holy days of RamzanMarch 31, 2025
Tired of Stomach Cramps? These Simple Foods Can Heal Your GutMarch 31, 2025
Regional growth booming for startups in 2024 - QBO Innovation studyMarch 31, 2025